Answers are grounded in this paper and cite their sources.
Background: GTP-bound mutant forms of H-Ras (Harvey-Ras) proteins are found in almost 30% of human tumors. In the present in silico study, the inhibitory effect of different flavonoid compounds on mutant H-Ras protein p21 has been assessed. The inhibitory effect of flavonoids is compared with three known clinical anticancer drugs. Besides, these have been interacted with normal H-Ras and tumor necrosis factor (TNF) proteins for toxicity check. Results: Upon docking, it was found that flavonoids such as naringenin, daidzein, and hesperetin showed highest affinity (most negative ΔG), while rutin showed no affinity towards mutant H-Ras. The three clinical anticancer agents (erlotinib, letrozole and exemestane) showed binding energies in the range of –1.11 to –5.51 kcal/mol which is comparatively lower than the flavonoids indicating efficacy of flavonoids to prevent complex formation with Raf and thereby prevent downstream effects. However, flavonoids showed no interaction with normal H-Ras and TNF indicating little or no cytotoxicity. Conclusion: Our study demonstrates that flavonoids (naringenin, daidzein, and hesperetin) are effective drugs to inhibit complex formation between mutant H-Ras P21 and RBD of Raf.
No takes yet. Share an insight, caveat, or question.
Alhamdan et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: